Study of Colchicine to Treat Acute Pericarditis and Prevent Recurrences

NCT ID: NCT00128453

Last Updated: 2012-06-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-08-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine whether colchicine is safe and effective in the treatment of acute pericarditis and the prevention of subsequent recurrences.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Colchicine is safe and effective in the management of recurrent pericarditis after failure of conventional treatment. Preliminary data have shown that it may be effective also in treatment of the index attack of pericarditis and the prevention of further recurrences.

Comparisons: The study will compare the safety and efficacy of colchicine in the treatment of acute pericarditis and the primary prevention of recurrences. Colchicine will be used in addition to conventional treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pericarditis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Conventional therapy plus placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo

Colchicine

Conventional therapy plus colchicine

Group Type ACTIVE_COMPARATOR

Colchicine (for 3 months)

Intervention Type DRUG

Colchicine 0.5mg BID (patients\>70Kg) or 0.5mg once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colchicine (for 3 months)

Colchicine 0.5mg BID (patients\>70Kg) or 0.5mg once daily

Intervention Type DRUG

Placebo

placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with acute pericarditis (index attack)
* Age≄ 18 years
* Informed consent

Exclusion Criteria

* Suspected neoplastic, tuberculous, or purulent etiology
* Known severe liver disease and/or elevated transaminases \>1.5 times the upper limit of normality
* Serum creatinine \>2.5 mg/dl
* Serum creatine kinase (CK) over the upper limit of normality or known myopathy
* Known gastrointestinal or blood disease
* Pregnant or lactating women or women not protected by a contraception method
* Known hypersensibility to colchicine
* Treatment with colchicine at enrolment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Azienda Sanitaria Locale 3, Torino

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rita TRINCHERO, MD

Role: STUDY_CHAIR

Cardiology Department. Maria Vittoria Hospital, ASL 3 Torino. Italy.

Massimo IMAZIO, MD

Role: STUDY_CHAIR

Cardiology Department. Maria Vittoria Hospital, ASL 3 Torino. Italy.

Massimo IMAZIO, MD

Role: PRINCIPAL_INVESTIGATOR

Cardiology Department. Maria Vittoria Hospital, ASL 3 Torino. Italy.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cardiology Department. Maria Vittoria Hospital, ASL 3 Torino

Torino, Torino, Italy

Site Status

Internal Medicine Division

Bergamo, , Italy

Site Status

Cardiology Department-Ospedale Regionale

Bolzano, , Italy

Site Status

Ospedale di Rivoli

Rivoli, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

References

Explore related publications, articles, or registry entries linked to this study.

Imazio M, Cecchi E, Ierna S, Trinchero R; ICAP Investigators. Investigation on Colchicine for Acute Pericarditis: a multicenter randomized placebo-controlled trial evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of pericarditis; study design amd rationale. J Cardiovasc Med (Hagerstown). 2007 Aug;8(8):613-7. doi: 10.2459/01.JCM.0000281702.46359.07.

Reference Type BACKGROUND
PMID: 17667033 (View on PubMed)

Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, Demarie D, Forno D, Ferro S, Maestroni S, Belli R, Trinchero R, Spodick DH, Adler Y; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013 Oct 17;369(16):1522-8. doi: 10.1056/NEJMoa1208536. Epub 2013 Aug 31.

Reference Type DERIVED
PMID: 23992557 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EUDRACT number 2005-001570-28

Identifier Type: -

Identifier Source: secondary_id

DCASL30501-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
NCT07010159 RECRUITING PHASE2/PHASE3
Colchicine in Acutely Decompensated HFREF
NCT06286423 RECRUITING PHASE4
Adrecizumab in Cardiogenic Shock
NCT03989531 COMPLETED PHASE2/PHASE3
Cell Therapy In Dilated Cardiomyopathy
NCT00333827 COMPLETED PHASE3